Description
NOTICE TO NOT EXERCISE THE FIRST OPTION YEAR FOR 36E79722D0014
Base award description: 4 LINES ITEMS FOR ALBUTEROL NEBULIZER. AWARDED FOR BASE YEAR OF 4/10/2022 TO 4/9/2023 PLUS 4 ONE-YEAR OPTION PERIODS.
Modification chain · 3 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2022-02-04+$0= $0
- Mod P000012023-01-12+$0= $0
- Mod P000022023-03-27+$0= $0
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2022-02-04 | +$0 | $0 | 4 LINES ITEMS FOR ALBUTEROL NEBULIZER. AWARDED FOR BASE YEAR OF 4/10/2022 TO 4/9/2023 PLUS 4 ONE-YEAR OPTION… |
| Mod P00001· ADD SUBCONTRACTING PLAN | 2023-01-12 | +$0 | $0 | 2023 SUBCONTRACTING PLAN |
| Mod P00002· OTHER ADMINISTRATIVE ACTION | 2023-03-27 | +$0 | $0 | NOTICE TO NOT EXERCISE THE FIRST OPTION YEAR FOR 36E79722D0014 |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI NDN1MYB8DKK5)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36E79726D0033 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2026 |
| 36E79725D0054 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2025 |
| 36E79723D0015 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2023 |
| 36F79723D0025 | NAC FEDERAL SUPPLY SCHEDULE (36F797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2023 |
| 36E79721N0050 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2021 |
| 36E79721N0043 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $116,444 | FY2021 |
Other recipients under 6505 from NAC PHARMACEUTICALS (36E797) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36E79726A0025 | CHIESI USA INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0024 | NEUROTECH PHARMACEUTICALS, INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0023 | TAKEDA PHARMACEUTICALS AMERICA, INC. | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726D0041 | GOLDEN STATE MEDICAL SUPPLY, INC. | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0022 | AURINIA PHARMA US INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_IDV_36E79722D0014_3600 · retrieved 2026-09-26.